The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback